A Prospective Cohort Study on the Pharmacokinetics and Risk Factors of Acute Kidney Injury Associated with Polymyxin B in Critically Ill Patients.

Population Pharmacokinetic Study of Polymyxin B in Critically Ill Adult Patients with Severe Infections

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600122537

Enrollment

Unknown

Registered

2026-04-15

Start date

2022-08-10

Completion date

Unknown

Last updated

2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with severe infections

Interventions

Case series:none

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Severe infection patients aged >=18 years; 2. Suspected/confirmed multi-drug resistant Gram-negative bacterial infection; 3. Received intravenous polymyxin B for >=48 hours.

Exclusion criteria

Exclusion criteria: 1.P atients who are allergic to polymyxin B; 2. Patients who died within 48 hours after receiving polymyxin B treatment; 3. Patients who are unable to provide blood samples; 4. Pregnant women.

Design outcomes

Primary

Measure	Time frame
serum drug concentration;	—

Countries

China

Contacts

Public ContactLuo Xuemei

Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.

yixuejiai@sina.com+86 139 1595 8238

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026